EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Acteoside relieves diabetic retinopathy through the inhibition of Müller cell reactive hyperplasia by regulating TXNIP and mediating Kir4.1 channels in a PI3K/Akt-dependent manner

Xiaoting Xi, Xiaolei Liu, Qianbo Chen, Jia Ma, Xuewei Wang, Yufei Gui, Yuxin Zhang, Yan Li iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0312565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Xiaoting Xi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology Department, The First Affiliated Hospital of Kunming Medical University, Kunming, China. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Ependymoglial Cells, Proto-Oncogene Proteins c-akt, Glucosides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China-Regional Science Foundation Project, Applied Basic Research in Yunnan Province (Joint Project of Kunming Medical University), Science and Technology Department of Yunnan Province-Major science and technology special plan of Yunnan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic retinopathy (DR) is a severe microangiopathy of diabetes. Müller cells play an important role in the development of DR. Acteoside (ACT) has been reported to be effective in the treatment of DR. In this study, we explored the molecular mechanism of ACT in the treatment of DR from the perspective of the reactive proliferation of Müller cells. The effect of ACT on DR was investigated via high-glucose (HG) treatment of Müller RMC-1 cells and an injection of streptozotocin (STZ) in constructed DR cells and animal models. The results showed that after ACT treatment, damage to the retinal structure in DR rats was alleviated, the number of hemangiomas was reduced, and the penetration of blood vessels was weakened. In addition, ACT treatment improved the hypertrophy and gliogenesis of Müller cells during DR, promoted the expression of Kir4.1 and activated the PI3K/Akt signaling pathway. ACT treatment inhibited the proliferation and migration of RMC-1 cells and promoted the expression of Kir4.1. TXNIP overexpression effectively reversed the inhibitory effect of ACT on the proliferation and migration of Müller cells and its induction of Kir4.1 expression. In addition, TXNIP knockdown effectively reversed the inhibitory effect of HG on the expression of p-PI3K and p-Akt, whereas TXNIP overexpression had the opposite effect, and treatment with the PI3K/AKT pathway inhibitor LY294002 effectively reversed the effect of TXNIP knockdown. Animal experiments also confirmed that the therapeutic effect of ACT on DR rats could be reversed by the overexpression of TXNIP or LY294002. In conclusion, ACT inhibits Müller cell reactive proliferation and alleviates diabetic retinopathy by regulating TXNIP and mediating the expression of Kir4.1 channels in a PI3K/Akt-dependent manner.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic RetinopathyEpendymoglial CellsProto-Oncogene Proteins c-aktGlucosidesPhosphatidylinositol 3-KinasesSignal TransductionPotassium Channels, Inwardly RectifyingCarrier ProteinsPhenolsAnimalsRatsMaleCell ProliferationDiabetes Mellitus, ExperimentalHyperplasiaRats, Sprague-DawleyCell LineGlucoseRetinaCell Cycle ProteinsPolyphenolsKcnj10 Channel

Substanzen

acteosideProto-Oncogene Proteins c-aktGlucosidesPhosphatidylinositol 3-KinasesTXNIP protein, ratKcnj10 ChannelPotassium Channels, Inwardly RectifyingCarrier ProteinsPhenolsGlucose

Autor:innen und Institutionen

  • Ophthalmology Department, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
  • Neurology Department, The First Affiliated Hospital of Kunming Medical University, Kunming, China.

ORCID-Profile: Yan Li

Förderung

  • National Natural Science Foundation of China-Regional Science Foundation Project
  • Applied Basic Research in Yunnan Province (Joint Project of Kunming Medical University)
  • Science and Technology Department of Yunnan Province-Major science and technology special plan of Yunnan Province
  • Yunnan High-level Scientific and Technological Talents and Innovation Team Selection Special Project-Technical Innovation Talent Training Object Project
  • National Natural Science Foundation of China- Regional Science Foundation Project
  • National Natural Science Foundation regional project
  • Science and Technology Department of Yunnan Province - Major science and technology special plan of Yunnan Province

Zitieren

APA

Xi, X., Liu, X., Chen, Q., Ma, J., Wang, X., Gui, Y., Zhang, Y., & Li, Y. (2024). Acteoside relieves diabetic retinopathy through the inhibition of Müller cell reactive hyperplasia by regulating TXNIP and mediating Kir4.1 channels in a PI3K/Akt-dependent manner. PLOS ONE. https://doi.org/10.1371/journal.pone.0312565

Vancouver

Xi X, Liu X, Chen Q, Ma J, Wang X, Gui Y, et al. Acteoside relieves diabetic retinopathy through the inhibition of Müller cell reactive hyperplasia by regulating TXNIP and mediating Kir4.1 channels in a PI3K/Akt-dependent manner. PLOS ONE. 2024. doi:10.1371/journal.pone.0312565

BibTeX
@article{Xi2024,
  author = {Xi, Xiaoting and Liu, Xiaolei and Chen, Qianbo and Ma, Jia and Wang, Xuewei and Gui, Yufei and Zhang, Yuxin and Li, Yan},
  title = {Acteoside relieves diabetic retinopathy through the inhibition of Müller cell reactive hyperplasia by regulating TXNIP and mediating Kir4.1 channels in a PI3K/Akt-dependent manner},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0312565}
}
Kostenlos starten →